IO Biotech Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
IOBT Nasdaq 8731 https://www.iobiotech.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for IO Biotech Inc

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness - Apr 15th, 2024 12:30 pm
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 - Apr 9th, 2024 4:00 pm
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer - Apr 5th, 2024 12:30 pm
IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials - Mar 7th, 2024 7:01 pm
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting - Mar 6th, 2024 9:11 pm
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results - Mar 5th, 2024 9:40 pm
IO Biotech to Present at 44th Annual Cowen Health Care Conference - Feb 26th, 2024 9:05 pm
IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24% - Jan 15th, 2024 11:59 am
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial - Dec 21st, 2023 1:30 pm
We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate - Dec 19th, 2023 11:43 am
IO Biotech Announces 2023 Third Quarter Results - Nov 13th, 2023 1:12 pm
IO Biotech Appoints Helen Collins, MD, to its Board of Directors - Nov 13th, 2023 1:00 pm
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma - Nov 10th, 2023 1:00 pm
IO Biotech Announces Participation in Upcoming Investor Conferences - Nov 8th, 2023 9:30 pm
This IO Biotech Insider Increased Their Holding In The Last Year - Nov 7th, 2023 11:02 am
IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting - Nov 1st, 2023 12:30 pm
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis - Oct 24th, 2023 4:30 pm
Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress - Oct 23rd, 2023 5:00 am
IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting - Oct 3rd, 2023 8:30 pm
IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer - Sep 12th, 2023 12:05 pm